• 1
    Harvey EB, Brinton LA. Second cancer following cancer of the breast in Connecticut, 1935–1982. Natl Cancer Inst Monogr 1985;68: 99112.
  • 2
    Teppo L, Pukkala E, Saxen E. Multiple cancer—an epidemiologic exercise in Finland. J Natl Cancer Inst 1985;75: 20717.
  • 3
    Adami HO, Krusemo UB, Bergkvist L, Persson I, Pettersson B. On the age-dependent association between cancer of the breast and of the endometrium. A nationwide cohort study. Br J Cancer 1987;55: 7780.
  • 4
    Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Silfversward C, Skoog L, Somell A, Theve T, Wilking N, et al. Adjuvant tamoxifen in early breast cancer, occurrence of new primary cancers. Lancet 1989: 1: 11720.
  • 5
    Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86: 52737.
  • 6
    Van Leeuwen FE, Benraadt J, Coebergh JWW, Kiemeney L, Gimbrère C, Otter R, Schouten LJ, Damhuis RA, Bontenbal M, Diepenhorst FW, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994;343: 44852.
  • 7
    Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 1995;87: 64551.
  • 8
    Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO, Campbell S. Effects of tamoxifen on the uterus and ovaries of women involved in a randomized breast cancer prevention trial. Lancet 1994;343: 131821.
  • 9
    Assikis VJ, Neven P, Jordan VC, Vergote I. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur J Cancer 1996;32A: 146476.
  • 10
    Furr BJ, Jordan VC. The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 1984;25: 127205.
  • 11
    Kallio S, Kangas L, Blanco G, Johansson R, Karjalainen A, Perilä M, Pippo I, Sundquist H, Sodervall M, Toivola R. 1986. A new triphenylethylene compound, Fc-1157a. I. Hormonal effects. Cancer Chemother Pharmacol 1986;17: 1038.
  • 12
    Hard GC, Iatropoulos MJ, Jordan K, Radi L, Kaltenberg OP, Imondi AR, Williams GM. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res 1993;53: 453441.
  • 13
    Karlsson S, Hirsimäki Y, Mäntylä E, Kangas L, Hirsimäki P, Perry CJ, Mulhern M, Millar P, Handa J, Williams GM. A two-year carcinogenicity study of the antiestrogen toremifene in Sprague-Dawley rats. Drug Chemical Toxicol 1996;19: 24566.
  • 14
    Davies A, Oreffo VI, Martin EA, Festing MF, White IN, Smith LL, Styles JA. Tamoxifen causes gene mutations in the livers of lambda/lacI transgenic rats. Cancer Res 1997;57: 128893.
  • 15
    World Medical Association. World Medical Association Declaration of Helsinki (
  • 16
    Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Constantino J, Redmond C, Fisher ER, Bowman DM, Deschenes L, Dimitrov NV, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor positive tumors. J Natl Cancer Inst 1996;88: 152942.
  • 17
    White INH, De Matteis F, Davies A, Smith LL, Crofton-Sleigh C, Venitt S, et al. Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis 1992;13: 2197203.
  • 18
    Hirsimäki P, Hirsimäki Y, Nieminen L, Payne BJ. Tamoxifen induces hepatocellular carcinoma in rat liver—a 1-year study with 2 antiestrogens. Arch Toxicol 1993;67: 4954.
  • 19
    Curtis RE, Boice JD, Shiner DA, Hankey BF, Fraumeni JF. Second cancers after adjuvant tamoxifen therapy for breast cancer. J Natl Cancer Inst 1996;88: 8324.
  • 20
    Mignotte H, Lasset C, Bonadona V, Lesur A, Luporsi E, Rodier JF, Cutuli B, Lasry S, Mauriac L, Granon C, Kerr C, Giard S, et al. Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Int J Cancer 1998;76: 32530.
  • 21
    Bernstein L, Deapen D, Cerhan JR, Schwartz SM, Liff J, McGann-Maloney E, Perlman JA, Ford L. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 1999;91: 165462.
  • 22
    Bergman L, Beelen MLR, Gallee MPW, Hollema H, Benraadt J, van Leeuwen FE, and the Comprehensive Cancer Centres' ALERT Group. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet 2000;356: 8817.
  • 23
    Teppo L, Pukkala E, Lehtonen M. Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol 1995;33: 14658.
  • 24
    Travis, LB, Curtis RE, Storm H, Hall P, Holowaty E, van Leeuwen FE, Kohler BA, Pukkala E, Lynch CF, Andersson M, Bergfeldt K, Clarke EA, et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 1997;89: 142939.
  • 25
    Metayer C, Lynch CF, Clarke EA, Glimelius B, Storm H, Pukkala E, Joensuu T, van Leeuwen FE, van't Veer MB, Curtis RE, Holowaty EJ, Andersson M, et al. Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence. J Clin Oncol 2000;18: 243543.